Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism. Issue 1 (June 2016)

• Record Type: Journal Article
• Authors: Stacy, Zachary; Call, William; Hartmann, Aaron; Peters, Golden; Richter, Sara
• Is Part Of: Cardiology and therapy. Volume 5:Issue 1(2016)
• Page Start: 1
• Page End: 18
• Publication Date: 2016-06
• Subjects: Atrial fibrillation -- Direct oral anticoagulant (DOAC) -- Edoxaban -- Factor Xa -- Factor Xa inhibitor -- Non-vitamin K oral anticoagulant (NOAC) -- Target-specific oral anticoagulant -- Venous thromboembolism -- Warfarin; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; Heart -- Diseases -- Treatment -- Periodicals; Cardiovascular Diseases -- Periodicals; 616.12005
• DOI: 10.1007/s40119-016-0058-2
• Languages: English
• ISSNs: 2193-8261

Abstract

Abstract Historically, vitamin K antagonists have been the only class of oral anticoagulants available. Despite our experience with warfarin over the past 60 years, its use is associated with several pharmacokinetic and clinical disadvantages including unpredictable dosing, frequent monitoring, and delayed onset and offset. Edoxaban, an oral direct Xa inhibitor, may provide clinicians with an additional option in patients requiring chronic anticoagulation. This review examines the pharmacology and clinical data of edoxaban as a therapeutic alternative.